title: Tofacitinib prevents radiographic progression in rheumatoid arthritis.
abstract: Tofacitinib, a novel Janus kinase inhibitor, may prevent structural damage in rheumatoid arthritis (RA). In this cohort study, we compared radiographic progression of hand joints between 21 RA patients who took tofacitinb for 18 months in a phase IIb and its extension study and 42 patients who took conventional disease modifying antirheumatic drugs (DMARDs), using simple erosion narrowing score. For tofacitinib group, changes before and after the treatment were also compared. The changes of erosion and sum scores were significantly less in tofacitinib than DMARDs group (for erosion, -0.60 ± 1.83 vs 0.51 ± 1.77, P = 0.038; for sum, -0.50 ± 1.72 vs 1.57 ± 4.13, P = 0.012). Joint space narrowing score (JSN) was also less in tofacitinib group (0.095 ± 0.58 vs 1.06 ± 2.60, P = 0.055). In tofacitinib group, yearly rates of both erosion and JSN were significantly decreased after administration of tofacitinib (For erosion, 0.62 ± 0.93 to -0.14 ± 0.48, P = 0.009; for JSN, 0.47 ± 0.64 to 0.03 ± 0.40, P = 0.032), as was change of sum score (1.09 ± 1.27 to -0.10 ± 0.63, P < 0.001). In conclusion, tofacitinib may prevent structural damage caused by RA.
authors: Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
authors: Joon Wan
authors: JW
authors: Kim
authors: In Ah
authors: IA
authors: Choi
authors: Eun Young
authors: EY
authors: Lee
authors: Yeong Wook
authors: YW
authors: Song
authors: Eun Bong
authors: EB
authors: Lee
mesh_terms: D000328:Adult; D000368:Aged; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000517:prevention & control; D015331:Cohort Studies; D018450:Disease Progression; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010880:Piperidines / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D011758:Pyrroles / Q000627:therapeutic use*; D011859:Radiography; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D018501:Antirheumatic Agents; D010880:Piperidines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D011758:Pyrroles; C479163:tofacitinib
keywords: Arthritis, Rheumatoid; Radiographic Progression; Tofacitinib
references: Ann Rheum Dis. 2010 Feb;69(2):413-6
references: 19587388
references: N Engl J Med. 2012 Aug 9;367(6):495-507
references: 22873530
references: Arthritis Rheum. 1998 Jul;41(7):1190-5
references: 9663474
references: Arthritis Rheum. 1992 Jan;35(1):26-34
references: 1731813
references: J Rheumatol. 1999 Mar;26(3):743-5
references: 10090194
references: Arthritis Rheum. 2012 Mar;64(3):617-29
references: 21952978
references: Nature. 1999 Nov 18;402(6759):304-9
references: 10580503
references: Blood. 2011 Feb 10;117(6):1938-46
references: 21106989
references: Arthritis Rheum. 1991 Jun;34(6):660-8
references: 2053913
references: Ann Rheum Dis. 2008 Sep;67(9):1267-70
references: 18203764
references: Rheum Dis Clin North Am. 2010 May;36(2):385-404
references: 20510240
references: Rheumatology (Oxford). 1999 Oct;38(10):941-7
references: 10534543
references: Arthritis Rheum. 2013 Mar;65(3):559-70
references: 23348607
references: Scand J Rheumatol. 2011;40(4):263-8
references: 21417549
references: J Med Chem. 2010 Dec 23;53(24):8468-84
references: 21105711
references: Arthritis Rheum. 2000 Sep;43(9):1927-40
references: 11014342
references: N Engl J Med. 2012 Aug 9;367(6):508-19
references: 22873531
references: Arthritis Res Ther. 2006;8(3):R76
references: 16646983
references: Arthritis Rheum. 2009 Jul;60(7):1895-905
references: 19565475
references: Rheumatology (Oxford). 2000 Jun;39 Suppl 1:9-16
references: 11001374
references: Ann Rheum Dis. 2008 Mar;67(3):375-9
references: 17644537
references: Lancet. 2013 Feb 9;381(9865):451-60
references: 23294500
references: Arthritis Rheum. 1988 Mar;31(3):315-24
references: 3358796
references: Ann Rheum Dis. 2010 Nov;69(11):1898-906
references: 20959326
references: Rheumatology (Oxford). 2002 Dec;41(12):1346-56
references: 12468813